Triplet Therapeutics, Inc.
 
Approach: antisense oligonucleotide targeting DNA damage response pathway
Status: Preclinical
   Website
   Dec. 17, 2019 Press Release
   Dec. 17, 2019 Endpoints Article
  Apr. 28, 2021 Genetic Eng New Article re: TTX-3360